App-Quantinova.ai

Efficacy of Obeticholic Acid Treatment Through 24 Months of Open‐Label Extension in Patients with Primary Biliary Cholangitis and Cirrhosis: Data From POISE

John M. Vierling - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary biliary cirrhosis

Alkaline phosphatase

Reductions in Abnormal Direct Bilirubin with Obeticholic Acid in Patients with Primary Biliary Cholangitis

Albert Pares - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary biliary cirrhosis

N/A

Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis.

Francesca Saffioti - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary sclerosing cholangitis

N/A

Early identification of candidates for second‐ line therapies in PBC using a UDCA‐response model

Marco Carbone - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Autoimmune liver disease in the UK: a national primary care evaluation of disease geoepidemiology

Gwilym Webb - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Exploring the Impact of Autoimmune Hepatitis on Health‐Related Quality of Life

Lin Lee Wong - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Autoimmune hepatitis

N/A

Multi‐parametric MRI imaging correlates with clinically meaningful surrogates of disease activity in autoimmune hepatitis

Katherine Arndtz - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Autoimmune hepatitis

N/A

B‐cell depletion with Rituximab demonstrates excellent laboratory efficacy at 6 months in patients with complicated autoimmune hepatitis

Daniel Schmidt-Martin - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Autoimmune hepatitis

Rituximab

Enhanced Immunoregulation Is Likely To Be The Mechanism Of Pregnancy‐Mediated Tolerance In Autoimmune Hepatitis

Muhammed Yuksel - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Autoimmune hepatitis

Interferon Gamma

The Extracellular Matrix (ECM) Turnover Profile In Cholestatic And Autoimmune Liver Diseases ‐ An Exploratory Study

Mette J. Nielsen - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

YAP Regulated SOX9 Expression Promotes Liver Fibrosis.

James Pritchett - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Hepatic fibrosis

verteporfin

Transforming growth factor beta and IL‐4/IL‐13 signaling collaborate to prevent abnormal cystic liver formation during Schistosoma mansoni infection.

David A. Cantu - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

IL-4

cRel controls epithelial reprogramming to promote hepatic fibrosis and tissue regeneration

Jack Leslie - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute Liver Injury

N/A

The role of mechanosensor molecules in HSCs durotaxis

Dariusz Lachowski - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Thyroid hormone (T3) regulates liver progenitor cell response

Paul P. Manka - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic steatohepatitis

N/A

Interleukin‐13 Activated Hedgehog Signaling Regulates Pathogen Driven Inflammation and Fibrosis

Thiago A. Pereira - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Portal Hypertension

Interleukin

SOX9 predicts progression of liver fibrosis in patients with chronic hepatitis C

Varinder S. Athwal - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

Plasma cell‐free DNA harbours novel genomewide methylome signatures associated with advanced fibrosis in non‐ alcoholic fatty liver disease

Timothy Hardy - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fatty Liver Disease

N/A

Performances of FibroScan® to detect large esophageal varices in chronic liver diseases patients are improved by a novel spleen‐dedicated examination

Horia Stefanescu - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Esophageal varices

EndoS

Effect of Hepatic Venous Pressure Gradient (HVPG) Changes on Cirrhosis Decompensation in Patients with Clinically‐Significant Portal Hypertension (CSPH)

Jordan Sack - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatic encephalopathy

Timolol

Filters

45280 Abstracts